The United States Preventive Services Task Force (USPSTF) is the most widely regarded source for information on US cancer screening. In 2012, the USPSTF gave prostate cancer screening a grade “D” recommendation, essentially guiding physicians and patients to discourage prostate cancer early detection.1 This recommendation may have had an adverse effect on prostate cancer incidence rates across risk groups, including potentially lethal cancers, and was widely decried by specialty and advocacy groups.2 The grade D recommendation was based on what is now known to be an incorrect interpretation of the clinical evidence supporting screening at the time and legitimate concerns about cancer overdetection and overtreatment (the detection and treatment of indolent cancers that would not have been a problem if left undiagnosed and untreated).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Carroll PR. USPTF Prostate Cancer Screening Recommendations—A Step in the Right Direction. JAMA Surg. 2018;153(8):701–702. doi:10.1001/jamasurg.2018.1283
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: